Genscript Biotech (1548) AI Stock Analysis

• Market Cap: $34.82B
• Dividend Yield: N/A
• Average Volume (3M): 11.61M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.15
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 5,568
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.17
• Shares Outstanding: 2,185,099,900
• 10 Day Avg. Volume: 8,707,016
• 30 Day Avg. Volume: 11,605,265
• PEG Ratio: -0.03
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 4.64
• P/FCF Ratio: -38.16
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 47.34
• Enterprise Value/Gross Profit: 91.42
• Enterprise Value/Ebitda: 65.75
• 1Y Price Target: $23.85
• Price Target Upside: 48.12% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 63 Neutral
• Price Target: HK$17.00 ▲(5.59% Upside)

Genscript Biotech's overall score is driven by strong revenue growth and positive earnings call highlights. However, challenges with profitability, negative valuation metrics, and bearish technical indicators weigh down the score.

Genscript Biotech Business Overview & Revenue Model

Company Description

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

How the Company Makes Money

Genscript Biotech generates revenue primarily through its diverse offerings in gene synthesis, protein production, and antibody services. The company operates on a B2B model, where it serves a wide array of clients including academic institutions, pharmaceutical companies, and biotechnology firms. Key revenue streams include custom gene synthesis, which involves creating specific DNA sequences for clients; peptide synthesis, where customized peptides are produced for research and therapeutic applications; and contract research services, which include various laboratory services for drug discovery and development. Additionally, Genscript benefits from strategic partnerships with other biotech firms and research institutions, enhancing its market reach and service offerings. The company's continuous investment in R&D and technological advancements also supports its revenue growth by enabling the introduction of new products and services to meet evolving market demands.

Genscript Biotech Financial Statement Overview

Summary

Genscript Biotech shows strong revenue growth and a solid balance sheet, but struggles with profitability and consistent cash flow. The company needs to improve operational efficiency and manage capital expenditures for sustainable success.

Income Statement

Genscript Biotech has shown significant revenue growth over the years, with a compound annual growth rate in revenue from 2019 to 2024. The gross profit margin remains strong, indicating efficient cost management. However, the company has struggled with profitability, as reflected in negative EBIT and net profit margins in several years, despite a positive net income in 2024 due to exceptional items. The trajectory indicates improving top-line growth but persistent challenges in achieving sustainable profitability.

Balance Sheet

The balance sheet reflects a strong equity position with the equity ratio consistently above 50%, indicating financial stability and low leverage. The debt-to-equity ratio is manageable, supporting a stable financial structure. Improvements in asset base and shareholder equity over the years suggest healthy growth, although fluctuations in cash reserves may indicate liquidity management challenges.

Cash Flow

Cash flow from operations has improved in 2024, turning positive after several years of negative figures, demonstrating progress in cash generation. Nonetheless, the free cash flow remains negative, impacted by significant capital expenditures and investments, which could pose liquidity risks. The operating cash flow to net income ratio improved, but long-term sustainability of positive cash flow remains uncertain without consistent profitability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	551.89M	594.49M	839.53M	625.70M	490.10M	390.85M
Gross Profit	285.77M	272.13M	270.63M	304.08M	282.52M	255.89M
EBITDA	397.29M	70.43M	-249.42M	-389.04M	-341.57M	-174.71M
Net Income	3.11B	2.96B	-95.48M	-226.85M	-358.71M	-204.94M
Balance Sheet
Total Assets	5.43B	5.28B	3.39B	2.55B	2.23B	1.45B
Cash, Cash Equivalents and Short-Term Investments	938.36M	621.18M	1.93B	1.46B	1.41B	772.38M
Total Debt	548.52M	723.74M	416.99M	349.80M	156.45M	55.00M
Total Liabilities	1.01B	954.91M	1.34B	1.18B	846.17M	631.82M
Stockholders Equity	4.42B	4.32B	1.39B	1.01B	1.05B	901.71M
Cash Flow
Free Cash Flow	200.49M	-72.27M	-444.62M	-336.40M	-269.83M	-272.97M
Operating Cash Flow	232.62M	75.65M	-286.91M	-120.29M	-136.79M	-151.09M
Investing Cash Flow	-98.64M	-1.46B	-357.73M	-443.30M	-212.55M	-100.17M
Financing Cash Flow	26.40M	66.52M	1.07B	419.32M	902.14M	624.20M

Genscript Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 16.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1548, the sentiment is Negative. The current price of 16.1 is below the 20-day moving average (MA) of 16.42, below the 50-day MA of 16.90, and above the 200-day MA of 14.09, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 45.63 is Neutral, neither overbought nor oversold. The STOCH value of 58.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1548.

Genscript Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6821	―	HK$39.47B	27.73	6.33%	1.40%	6.43%	-0.96%
2696	―	HK$38.94B	43.75	27.37%	―	2.57%	18.79%
1548	―	$34.82B	―	―	―	―	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1877	―	HK$38.08B	-21.94	-15.06%	―	39.02%	48.26%
9688	―	HK$22.73B	―	-29.51%	―	32.07%	33.55%

Genscript Biotech Corporate Events

Genscript Biotech Reports Strong CARVYKTI® Sales in Q3 2025

Genscript Biotech Corporation announced that its associate, Legend Biotech, reported approximately $524 million in net trade sales for CARVYKTI® in the quarter ending September 2025. This figure highlights the product’s strong market performance under the collaboration with Janssen Biotech, Inc., indicating a positive impact on the company’s operations and industry positioning.

The most recent analyst rating on (HK:1548) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.

Genscript Biotech’s ProBio Receives Significant Sublicense Revenue Boost

Genscript Biotech Corporation announced that its subsidiary, ProBio, received approximately RMB479.7 million (US$67.5 million) as the second installment of sublicense revenue under an agreement with LaNova Medicines Ltd. This payment is related to the sublicense of anti-PD-1 single domain antibodies, which are part of LaNova’s investigational PD-1/VEGF bispecific antibody, LM-299. The cumulative payments received under this agreement now total approximately RMB2.0 billion (US$283.6 million). These funds will enhance ProBio’s cash reserves and support further molecular discovery and development, reinforcing its position in the biotechnology market.

The most recent analyst rating on (HK:1548) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.

Genscript Biotech Grants Share Awards to Boost Employee Engagement

Genscript Biotech Corporation announced the grant of 774,960 Share Awards under its 2019 RSU Scheme to an executive director and employee grantees. This move is part of the company’s strategy to align employee incentives with performance, featuring a vesting period of approximately three years and a clawback mechanism to ensure compliance with performance targets. The initiative reflects Genscript’s commitment to fostering employee engagement and maintaining robust corporate governance.

The most recent analyst rating on (HK:1548) stock is a Buy with a HK$24.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.

GenScript Biotech’s Earnings Call Highlights Robust Growth

GenScript Biotech Corporation’s recent earnings call conveyed a predominantly positive sentiment, underscored by substantial revenue growth across all segments and the impressive performance of Legend Biotech’s CAR-T product. Despite facing challenges such as net losses and temporary impacts on gross margins, the company’s achievements and growth prospects were highlighted as outweighing these difficulties.

Genscript Biotech Reports Strong Revenue Growth Amid Strategic Investments

Genscript Biotech Corporation, a Cayman Islands-incorporated company, operates in the biotechnology sector, providing life-science services and tools, biologics development services, and industrial synthetic biology products. It also holds significant investments in Legend Biotech Corporation, a company focused on cell therapy development.

Genscript Biotech Reports Strong Revenue and Profit Growth in H1 2025

Genscript Biotech Corporation reported significant financial growth in its unaudited consolidated interim results for the first half of 2025. The company achieved an 81.9% increase in revenue from continuing operations, amounting to approximately US$518.8 million, and a 140.1% rise in gross profit to US$320.6 million. Despite a net loss of US$24.5 million, largely due to a US$193.7 million share of loss from Legend Group, the adjusted net profit surged by 509.6% to US$178.0 million. This financial performance highlights Genscript’s robust business operations and strategic positioning in the biotech industry, with positive implications for stakeholders as the company continues to enhance its market presence.

Genscript Biotech’s Associate Legend Biotech Reports Q2 2025 Financial Results

Genscript Biotech Corporation announced that its associate, Legend Biotech Corporation, has released its financial results for the second quarter of 2025. The results, filed with the SEC, highlight Legend Biotech’s recent business achievements. Shareholders are advised to consider investment risks when dealing with Genscript’s securities.

Genscript Biotech Schedules Board Meeting for Interim Results Review

Genscript Biotech Corporation has announced a board meeting scheduled for August 16, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the possibility of declaring an interim dividend, which could have implications for the company’s financial strategy and shareholder returns.